• Company
    About us Business Development
  • Our Focus
    Our Focus Managed Access Programme
  • Research Areas (current)
  • News (current)
  • Careers
    Current Vacancies Talent Community
  • Contact
    Our Details Medical Information Product Safety
Your browser does not support the video tag.

Courage
For Life

News

BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease

03/12/2021

Read More …

BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma

17/08/2021

Read More …

EUSA Pharma Announces Appointment of Carsten Thiel as New Chief Executive Officer

30/03/2021

Read More …

SYLVANT® (siltuximab) Recommended by the National Comprehensive Cancer Network® (NCCN®) as the Preferred Treatment Option for Patients with Idiopathic Multicentric Castleman Disease (iMCD) regardless of histopathologic subtype

25/02/2021

Read More …

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China

25/01/2021

Read More …

EUSA Pharma To Present at the 39th Annual J.P. Morgan Healthcare Conference

11/01/2021

Read More …

EUSA Pharma Announces First Patient Enrolled in a Randomised Phase 3 Clinical Trial Investigating Siltuximab in Hospitalised Patients with COVID-19- or Another Respiratory Virus Infection-Associated Acute Respiratory Distress Syndrome (ARDS)

17/12/2020

Read More …

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China

09/11/2020

Read More …

EUSA Pharma are proud to be featured in this year’s Sunday Times Sage Tech Track 100

EUSA Pharma are proud to be featured in this year’s Sunday Times Sage Tech Track 100 as one of Britain’s private technology companies with the fastest-growing sales.

07/09/2020

Read More …

EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients with COVID-19 Associated Acute Respiratory Distress Syndrome

02/07/2020

Read More …
  • «
  • 1 (current)
  • 2
  • 3
  • 4
  • » Next

Company

  • About us
  • Business Development

Our Focus

  • Our Focus
  • Managed Access Programme

Contact

  • Our Details
  • Product Safety
  • Research Grants

Legal

  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Anti-modern Slavery Statement
  • Ethics and Compliance Reporting
  • Risk Assessment
  • HCP Privacy Notice
  • Social Community Guidelines
  • © 2023 EUSA Pharma (UK) Limited is a Recordati Group Company. All rights reserved.
  • GL-NPS-2000013
  • Date of prep: December 2022
You are about to leave the Global HQ (UK) area of eusapharma.com
You are now leaving EUSAPharma.com

Medical practices and regulations can vary from one country to another. As a result, the medical information provided in the area which you are about to visit may not be appropriate for product use in your country.

If you wish to continue to the area of eusapharma.com, please click 'Proceed'.

The link you have clicked will take you to an external site not owned or controlled by EUSA Pharma.

Cancel Proceed